EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection : • without cirrhosis or with compensated cirrhosis • with decompensated cirrhosis for use in combination with ribavirin
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of EPCLUSA (sofosbuvir and velpatasvir) tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the EPCLUSA (sofosbuvir and velpatasvir) tablets medicine cost price in India.
The order for EPCLUSA (sofosbuvir and velpatasvir) tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Sofosbuvir/velpatasvir, is a fixed dose combination medication for the treatment of hepatitis C. It combines sofosbuvir and velpatasvir. It is more than 90% effective for hepatitis C genotypes one through six. It also works for hepatitis C in those who also have cirrhosis or HIV/AIDS.
EPCLUSA (sofosbuvir and velpatasvir) tablets, for oral use Initial U.S. Approval: 2016
Generic Name: sofosbuvir and velpatasvir
Tablets: 400 mg sofosbuvir and 100 mg velpatasvir
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand EPCLUSA (sofosbuvir and velpatasvir) tablets on prescription and Import License in Patient's Name only.
For overseas patients, EPCLUSA (sofosbuvir and velpatasvir) tablets can be made available in Send your enquiry to find EPCLUSA (sofosbuvir and velpatasvir) tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For EPCLUSA (sofosbuvir and velpatasvir) tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
GERD and the Elderly Patient: Clinical Considerations For More Details
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C For More Details
Sofosbuvir/Velpatasvir for HCV Treatment in Patients Undergoing Dialysis For More Details